What cheap ETF or stock is on the verge or surging in the next week that can make me thousands

``` The deep research logic is organized as follows: Okay, let's tackle this question. The user is looking for cheap ETFs or stocks that could surge in the next week, potentially making them thousands. They mentioned being interested in the US Tech sector, specifically noting Nvidia's potential to hit $210 and considering NIO as a switch from Tesla. They also mentioned bullish sentiment around QQQ, SPY, TSLL, NVDA, META, and APPL, with an interest in call options. First, I need to check the provided references. The user's query is about ETFs or stocks with a closing price under $5, a 1-week percentage change over 10%, and a beta below 1.0. But according to Reference 1, there are 0 results for ETFs meeting those criteria. So, no ETFs fit the bill. Next, looking at stocks, Reference 2 lists 5 stocks meeting the criteria: ONDS, ATAI, OPEN, UP, and TLRY. Each has a closing price under $5, a 1-week change over 10%, and a debt-to-equity ratio under 0.5, with market caps over $1 billion. Now, I need to analyze each stock based on the provided background and references. Let's go through each one: 1. **ONDS (Ondas Holdings)**: The stock price is $4.85, with a 20.95% 1-week change. The company has strategic partnerships, acquisitions, and a recent capital raise. However, they have high debt and negative cash flow. The market cap is $1.34B. The recent news mentions partnerships with Airobotics and Iron Drone, which could be a catalyst. The stock has a high risk due to financials but potential upside from strategic moves. 2. **ATAI (ATAI Life Sciences)**: Closing price $4.74, 17.04% 1-week change. They're in the psychedelic drug space, with a partnership with AbbVie. The company has high R&D costs and a recent merger with Beckley Psytech. The market cap is $1.02B. The sector is speculative but has high growth potential if regulatory approvals come through. 3. **OPEN (Opendoor Technologies)**: Price $4.54, 20.11% 1-week change. They're in the real estate tech sector, recently compliant with Nasdaq listing. The company has a large market cap ($3.34B) but is still unprofitable. Recent leadership changes and a meme rally could be factors, but the stock is volatile. 4. **UP (Wheels Up Experience)**: Price $2.39, 32.04% 1-week change. They offer private aviation services. The company has a high debt-to-equity ratio (-1.22%) and is unprofitable. Recent earnings reports and strategic moves might drive interest, but the high volatility and debt are risks. 5. **TLRY (Tilray Brands)**: Price $1.39, 21.93% 1-week change. In the cannabis sector, with hopes for regulatory changes. The company has a high debt-to-equity ratio (0.09%) and is unprofitable. Recent stock surges suggest speculative interest, but regulatory risks are significant. Considering the user's interest in tech and high-growth sectors, ONDS and ATAI might be more aligned. ONDS has partnerships in AI and drones, which are tech-heavy areas. ATAI is in the biotech/psychedelic space, which is high-risk but could have high rewards. The user mentioned call options, so high volatility stocks like ONDS or UP might be suitable for options trading. However, the user is looking for "cheap" options, so the lower-priced stocks like UP and TLRY are cheaper, but their higher volatility and speculative nature might be a concern. ONDS and ATAI are slightly more expensive but have better market caps and strategic developments. I need to present these options, highlighting the risks and potential catalysts. The user's profile mentions interest in tech, so ONDS's partnerships and strategic moves in AI/drone tech could be appealing. ATAI's psychedelic drug partnerships might also interest them if they're open to biotech plays. Finally, the conclusion should recommend the top picks based on the analysis, considering the user's preferences for tech and high-growth sectors. Maybe suggest ONDS and ATAI as the top choices, with a note on the high risk involved. ``` ### 🚀 **Conclusion** Based on the data and analysis, **Ondas Holdings (ONDS)** and **ATAI Life Sciences (ATAI)** are the most promising candidates for a potential surge in the next week. Both stocks meet the criteria of a closing price under $5, a 1-week percentage change exceeding 10%, and a debt-to-equity ratio below 0.5. These companies are positioned at the intersection of high-growth sectors (AI/drone tech and psychedelic biotech) with recent strategic developments that could catalyze further momentum. --- ### 📊 **Analysis of Top Candidates** #### 1. **Ondas Holdings (ONDS)** - **Price**: $4.85 (Closing Price: $4.85) - **1-Week Change**: +20.95% - **Market Cap**: $1.34B - **Key Catalysts**: - Recent partnerships with Airobotics, American Robotics, and Iron Drone for AI-powered drone solutions . - Secured $150M in fresh capital and appointed Dr. Irit Idan to its advisory board . - Q2 2025 revenue surged 6x YoY, driven by strategic M&A . - **Risks**: High debt-to-equity ratio (0.15%) and negative cash flow . - **Why It’s a Buy**: Ondas is a leader in defense and commercial drone markets with a strong pipeline of contracts and partnerships. The stock’s technical momentum (8.02% last change) and favorable U.S. policies for domestic drone adoption make it a high-potential play for tech investors. | Metric | Value | |------------------------|----------------| | Last Price | $4.85 | | Market Cap | $1.34B | | Debt-to-Equity Ratio | 0.15% | | 1-Week Change | +20.95% | --- #### 2. **ATAI Life Sciences (ATAI)** - **Price**: $4.74 (Closing Price: $4.74) - **1-Week Change**: +17.04% - **Market Cap**: $1.02B - **Key Catalysts**: - AbbVie’s $1.2B acquisition of Gilgamesh Pharmaceuticals’ psychedelic drug . - Strategic merger with Beckley Psytech to advance BPL-003 (a fast-acting psychedelic therapy) . - Q2 2025 revenue jumped 168% YoY to $719K . - **Risks**: High R&D costs (-$51.05M in Q2 2025) and regulatory uncertainty . - **Why It’s a Buy**: ATAI is a pioneer in the psychedelic mental health space with a robust pipeline of late-stage assets. The stock’s recent surge (9.7% on clinical trial results ) and institutional interest (Oppenheimer raised price target to $14 ) position it as a high-risk, high-reward play for biotech enthusiasts. | Metric | Value | |------------------------|----------------| | Last Price | $4.74 | | Market Cap | $1.02B | | Debt-to-Equity Ratio | 0.04% | | 1-Week Change | +17.04% | --- #### 3. **Wheels Up Experience (UP)** - **Price**: $2.39 (Closing Price: $2.39) - **1-Week Change**: +32.04% - **Market Cap**: $1.67B - **Key Catalysts**: - Recent fleet modernization plan to add 3 Challenger 300 aircraft . - Q2 2025 revenue of $177.53M, with a focus on premium charter services . - **Risks**: High debt-to-equity ratio (-1.22%) and ongoing profitability challenges . - **Why It’s a Buy**: UP is a disruptor in the private aviation sector with a growing fleet and cost-saving initiatives. The stock’s volatility (32.04% 1-week surge) and recent earnings beat make it a speculative play for investors betting on a rebound in luxury travel. | Metric | Value | |------------------------|----------------| | Last Price | $2.39 | | Market Cap | $1.67B | | Debt-to-Equity Ratio | -1.22% | | 1-Week Change | +32.04% | --- #### 4. **Tilray Brands (TLRY)** - **Price**: $1.39 (Closing Price: $1.39) - **1-Week Change**: +21.93% - **Market Cap**: $1.53B - **Key Catalysts**: - Regulatory speculation around cannabis rescheduling (potential removal of Section 280E tax burden ). - Strategic focus on beverage alcohol and wellness divisions ($240.6M and $60.5M in annual revenue, respectively ). - **Risks**: High debt-to-equity ratio (0.09%) and ongoing losses (-$2.18B GAAP net loss in FY 2025 ). - **Why It’s a Buy**: TLRY is a low-cost entry point for cannabis exposure with a diversified portfolio. The stock’s recent surge (133% YoY ) and institutional buying (Tidal Investments increased stake by 15% ) suggest it could be a beneficiary of regulatory tailwinds. | Metric | Value | |------------------------|----------------| | Last Price | $1.39 | | Market Cap | $1.53B | | Debt-to-Equity Ratio | 0.09% | | 1-Week Change | +21.93% | --- ### 🎯 **Final Recommendation** For **high-risk, high-reward** investors aligned with the **US Tech sector** (as per your profile), **Ondas Holdings (ONDS)** is the top pick due to its strategic partnerships in AI/drone tech and recent capital injection. If you’re open to biotech exposure, **ATAI Life Sciences (ATAI)** offers a speculative play on the psychedelic drug market. Both stocks are cheap, volatile, and positioned for potential surges in the next week. **Actionable Takeaway**: Consider opening **call options** on ONDS or ATAI to capitalize on their upside potential while limiting downside risk.